rss
J Med Genet 2009;46:405-406 doi:10.1136/jmg.2008.063610
  • Letters to JMG

Do mutations of the Pendred syndrome gene, SLC26A4, confer resistance to asthma and hypertension?

  1. A C Madeo1,2,
  2. A Manichaikul3,
  3. S P Pryor2,
  4. A J Griffith2
  1. 1
    National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland USA
  2. 2
    National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, Maryland USA
  3. 3
    Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA
  1. A J Griffith, National Institutes of Health, 5 Research Court, Rockville, Maryland 20850-3320, USA; griffita{at}nidcd.nih.gov
  • Received 1 October 2008
  • Revised 5 February 2009
  • Accepted 13 February 2009
  • Published Online First 15 March 2009

Abstract

Background and aims: Mutations of SLC26A4 cause Pendred syndrome, an autosomal recessive disorder comprising goitre and deafness with enlarged vestibular aqueducts (EVA). Recent studies in mouse models implicate Slc26a4 in the pathogenesis of asthma and hypertension. We hypothesise that asthma and hypertension are less prevalent among humans with SLC26A4 mutations.

Methods: We reviewed medical histories and SLC26A4 genotypes for 80 individuals with EVA and 130 of their unaffected family members enrolled in a study of EVA. We used Fisher’s exact test to compare the prevalence of asthma and hypertension among groups of subjects with zero, one, or two mutant alleles of SLC26A4.

Results: Although none of the 21 subjects with two mutant alleles of SLC26A4 had asthma or hypertension, there were no statistically significant differences in the prevalence of asthma or hypertension among subjects with zero, one, or two mutant alleles.

Conclusion: There might be a protective effect of SLC26A4 mutations for asthma and hypertension but our study is statistically underpowered to detect this effect. Study sizes of at least 1125 and 504 individuals will be needed for 80% power to detect an effect at α = 0.05 for asthma and hypertension, respectively. Our hypothesis merits a larger study since it has implications for potential strategies to treat hearing loss by manipulating SLC26A4 expression or function.

Footnotes

  • Funding: We are supported by NIH intramural research funds Z01-DC000060 and Z01-DC000064 and the Intramural Research Program of the National Human Genome Research Institute.

  • Competing interests: None.

  • Patient consent: Obtained.

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JMG.
View free sample issue >>

Free archive
The full back archive is now available for JMG. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest genetics jobs

    Latest genetics jobs